bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version foresite capital  wikipedia foresite capital from wikipedia the free encyclopedia jump to navigation search foresite capital industry venture capital growth equity founded  founder jim tananbaum ceo website wwwforesitecapitalcom foresite capital is an american venture capital and growth equity firm the company has offices in san francisco and new york as of may  the company had raised three funds foresite capital fund i ii and iii historyedit foresite capital was founded in  by jim tananbaum cofounder of theravance who became ceo of the company foresite capital raised its  million fund i in  foresite has invested in companies such as epizyme intarcia therapeutics aerie pharmaceuticals muse bio and universal american foresite has funded x genomics since its series a round in november  and led its series b round in january  as well as its series c round in march  in april  foresite closed foresite capital fund ii a  million fund foresite capital fund iii a  million fund was closed in july  referencesedit  a b c david holley  july  foresite capital keeps latestage healthcare focus with m third fund xconomy retrieved  may    brian gormley  january  growthequity firm foresite capital raises m for debut healthcare fund wall street journal retrieved  may    damian garde  july  foresite capital reloads with a m biotech venture fund fierce biotech retrieved  may    foresite capital raises m to invest in latestage healthcare companies san francisco business times  january  retrieved  may    a b c eric blattberg  april  health care venture firm foresite capital closes m fund venture beat retrieved  may    ben fidler  november  karyopharm prices upsized ipo at  per share begins trading today xconomy retrieved  may    luke timmerman  january  foresite capital closes m fund for latestage biotechs xconomy retrieved  may    dan primack  september  diabetes ‘unicorn’ raises final vc round before ipo fortune retrieved  may    here’s who stands to gain from intarcia’s success with a type  diabetes pump boston business journal  october  retrieved  may    ed lin  october  aerie stock hits record high holder sells  million barrons retrieved  may    muse bio closes m series b financing round genome web retrieved  may    nick paul taylor  march  x genomics scoops another m to fuel commercialization of longread tech fierce biotech retrieved  may    alex lash  january  x genomics emerges with m and toastersized sequencer upgrade xconomy retrieved  may    a b damian gards  april  foresite banks m to bet on latestage biotechs fierce biotech retrieved  may   this article about a financial services corporation of the united states is a stub you can help wikipedia by expanding it v t e retrieved from httpsenwikipediaorgwindexphptitleforesitecapitaloldid categories venture capital firms of the united statesamerican companies established in united states financial services company stubshidden categories all stub articles navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  may  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view foresite capital  wikipedia foresite capital from wikipedia the free encyclopedia jump to navigation search foresite capital industry venture capital growth equity founded  founder jim tananbaum ceo website wwwforesitecapitalcom foresite capital is an american venture capital and growth equity firm the company has offices in san francisco and new york as of may  the company had raised three funds foresite capital fund i ii and iii historyedit foresite capital was founded in  by jim tananbaum cofounder of theravance who became ceo of the company foresite capital raised its  million fund i in  foresite has invested in companies such as epizyme intarcia therapeutics aerie pharmaceuticals muse bio and universal american foresite has funded x genomics since its series a round in november  and led its series b round in january  as well as its series c round in march  in april  foresite closed foresite capital fund ii a  million fund foresite capital fund iii a  million fund was closed in july  referencesedit  a b c david holley  july  foresite capital keeps latestage healthcare focus with m third fund xconomy retrieved  may    brian gormley  january  growthequity firm foresite capital raises m for debut healthcare fund wall street journal retrieved  may    damian garde  july  foresite capital reloads with a m biotech venture fund fierce biotech retrieved  may    foresite capital raises m to invest in latestage healthcare companies san francisco business times  january  retrieved  may    a b c eric blattberg  april  health care venture firm foresite capital closes m fund venture beat retrieved  may    ben fidler  november  karyopharm prices upsized ipo at  per share begins trading today xconomy retrieved  may    luke timmerman  january  foresite capital closes m fund for latestage biotechs xconomy retrieved  may    dan primack  september  diabetes ‘unicorn’ raises final vc round before ipo fortune retrieved  may    here’s who stands to gain from intarcia’s success with a type  diabetes pump boston business journal  october  retrieved  may    ed lin  october  aerie stock hits record high holder sells  million barrons retrieved  may    muse bio closes m series b financing round genome web retrieved  may    nick paul taylor  march  x genomics scoops another m to fuel commercialization of longread tech fierce biotech retrieved  may    alex lash  january  x genomics emerges with m and toastersized sequencer upgrade xconomy retrieved  may    a b damian gards  april  foresite banks m to bet on latestage biotechs fierce biotech retrieved  may   this article about a financial services corporation of the united states is a stub you can help wikipedia by expanding it v t e retrieved from httpsenwikipediaorgwindexphptitleforesitecapitaloldid categories venture capital firms of the united statesamerican companies established in united states financial services company stubshidden categories all stub articles navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  may  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view foresite capital management llc private company information  bloomberg july    pm et capital markets company overview of foresite capital management llc snapshot people company overview foresite capital management llc is a private equity and venture capital firm specializing in middle market buyouts growth capital and late stage investments it focuses on emerging disruptive service companies in the healthcare drug healthcare services therapeutics medical devices and service sector with late stage products or technology it targets investments in biotechnology genomics and diagnostics the firm seeks to invest between  million and  million foresite capital mangement llc was founded in  and is based in san francisco california with an additional office in new york new york  montgomery streetsuite san francisco ca united statesfounded in  phone  fax  wwwforesitecapitalcom key executives for foresite capital management llc dr james b tananbaum md mba chief executive officer founder and managing director age  mr dennis d ryan cpa chief financial officer and managing director ms christine aylward managing director dr dorothy j margolskee md managing director mr matthew buten managing director compensation as of fiscal year  foresite capital management llc key developments foresite capital appoints molly he as venture partner apr   foresite capital announced that it has named molly he phd as venture partner a former senior director at illumina dr he brings to company more than  years of experience in pharmaceutical and genomic research and development as senior director of scientific research at illumina dr he was responsible for the company’s global protein reagent innovation and improvements prior to illumina she was the head of protein sciences at pacific biosciences where she was responsible for protein reagent development for the company’s single molecular realtime sequencing chemistry similar private companies by industry company name region visory llc united states  road partners llc united states t partners llc united states jumpcom inc united states  ontario inc united states recent private companies transactions typedate target private placement july   venatorx pharmaceuticals inc private placement april   healthverity inc private placement march   solid biosciences llc request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact foresite capital management llc please visit wwwforesitecapitalcom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close zafgen nasdaqzfgn stock price news  analysis  marketbeat zafgen company profile nasdaqzfgn company profile analyst ratings earnings history earnings estimates dividend history insider trade headlines social media chart about zafgen nasdaqzfgn zafgen inc is a biopharmaceutical company the company is focused on improving the health and wellbeing of patients affected by obesity and complex metabolic disorders the companys lead product candidate beloranib is a twiceweekly subcutaneous injection being developed for the treatment of multiple indications including severe obesity in rare diseases such as praderwilli syndrome pws and hypothalamic injuryassociated obesity hiao including craniopharyngiomaassociated obesity beloranib is in phase iii stage of development for pws it is also developing zgn a livertargeted methionine aminopeptidase  metap inhibitor for the treatment of nonalcoholic steatohepatitis nash and abdominal obesity as well as other secondgeneration metap inhibitors for the treatment of severe obesity it is also evaluating additional metap inhibitors beyond beloranib as a development candidate for the treatment of severe obesity in the general population industry sector and symbol sector medical industry bio therapeutic drugs subindustry na symbol nasdaqzfgn cusip na web wwwzafgencom capitalizationmarket cap  millionoutstanding shares average prices day moving avg  day moving avg  week range    petrailing pe ratio naforeward pe ratio pe growth sales  book valueannual revenue naprice  sales nabook value  per shareprice  book  profitabilityebidta return on equity return on assets debtcurrent ratio quick ratio miscaverage volume  shsbeta short ratio    frequently asked questions for zafgen nasdaqzfgn what is zafgens stock symbol zafgen trades on the nasdaq under the ticker symbol zfgn how were zafgens earnings last quarter zafgen inc nasdaqzfgn issued its earnings results on tuesday may th the company reported  eps for the quarter missing the zacks consensus estimate of  by  view zafgens earnings history when will zafgen make its next earnings announcement zafgen is scheduled to release their next quarterly earnings announcement on wednesday august nd  view earnings estimates for zafgen where is zafgens stock going where will zafgens stock price be in   analysts have issued  year target prices for zafgens stock their predictions range from  to  on average they expect zafgens share price to reach  in the next twelve months view analyst ratings for zafgen what are analysts saying about zafgen stock here are some recent quotes from research analysts about zafgen stock  according to zacks investment research zafgen inc is a biopharmaceutical company the company develops therapeutics for patients suffering from obesity and obesityrelated disorders its lead product candidate includes beloranib an injection that is in phase ii clinical trials for the treatment of various indications comprising obesity and hyperphagia in praderwilli syndrome patients craniopharyngiomaassociated obesity and severe obesity in the general population zafgen inc is headquartered in cambridge massachusetts    cowen and company analysts commented zafgen reported a q net loss of mm ended  with mm in cash  are investors shorting zafgen zafgen saw a decrease in short interest during the month of june as of june th there was short interest totalling  shares a decrease of  from the june th total of  shares based on an average daily volume of  shares the daystocover ratio is presently  days currently  of the shares of the stock are short sold who are some of zafgens key competitors some companies that are related to zafgen include foamix pharmaceuticals fomx zymeworks zyme athersys athx redhill biopharma rdhl summit therapeutics plc smmt xbiotech xbit acelrx pharmaceuticals acrx kindred biosciences kin synthetic biologics syn sorrento therapeutics srne conatus pharmaceuticals cnat trevena trvn axsome therapeutics axsm agile therapeutics agrx recro pharma reph cellular biomedicine group cbmg arrowhead pharmaceuticals arwr and verastem vstm who are zafgens key executives zafgens management team includes the folowing people peter barrett phd independent chairman of the boardthomas e hughes phd president chief executive officer directorpatricia l allen cpa chief financial officerdennis d kim md chief medical officerbruce l booth phd directorthomas o daniel md directorgeoffrey mcdonough md directorrobert j perez directorfrances k heller jd independent director who owns zafgen stock zafgens stock is owned by a variety of of retail and institutional investors top institutional investors include spark investment management llc  and acadian asset management llc  company insiders that own zafgen stock include avi y goldberg dennis d kim frances k heller james e flynn kevin p starr patricia l allen and thomas e hughes view institutional ownership trends for zafgen who bought zafgen stock who is buying zafgen stock zafgens stock was bought by a variety of institutional investors in the last quarter including spark investment management llc and acadian asset management llc company insiders that have bought zafgen stock in the last two years include dennis d kim frances k heller james e flynn patricia l allen and thomas e hughes view insider buying and selling for zafgen how do i buy zafgen stock shares of zafgen can be purchased through any online brokerage account popular online brokerages include vanguard brokerage services td ameritrade etrade scottrade fidelity and charles schwab what is zafgens stock price today one share of zafgen stock can currently be purchased for approximately  marketbeat community rating for zafgen nasdaq zfgncommunity ranking   out of    outperform votes   vote outperformunderperform votes   vote underperformtotal votes  marketbeats community ratings are surveys of what our community members think about zafgen and other stocks vote outperform if you believe the stock will outperform the sp  over the long term vote underperform if you believe the stock will underperform the sp  over the long term you may vote once every thirty days analyst ratings consensus ratings for zafgen nasdaqzfgn how are consensus ratings calculated marketbeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months since brokers often use different ratings systems each rating is normalized to a standardized rating score of  sell  hold  buy or  strong buy consensus ratings scores are calculated using the mean average of the number of normalized sell hold buy and strong buy ratings each stocks consensus rating is derived from its calculated consensus ratings score   sell   hold   buy   strong buy marketbeats consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve monthsmarketbeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and marketbeat has received a report that coverage was dropped ratings from certain research firms that issue ratings using purely quantitative methods such as zacks vetr and valuengine are not included in consensus calculations marketbeats consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available dataratings breakdown  hold rating  buy ratingconsensus ratingbuy score consensus price target   upside analysts ratings history for zafgen nasdaqzfgn show only the most recent rating from each brokerage all ratings for this stock datefirmactionratingprice targetimpact on share pricedetailsroth capitalinitiated coveragebuy  buyhighcowen and companyreiterated ratingholdnafbr  coreiterated ratingmarketperformlowcanaccord genuityset price targethold  naleerink swannreiterated ratingmarket performnaroyal bank of canadareiterated ratingoutperformnasuntrust banks increiterated ratingholdnajmp securitiesdowngradeoutperform  market performnadata available from  forward earnings earnings history for zafgen nasdaqzfgnearnings history by quarter for zafgen nasdaq zfgndatequarterconsensus estimateactual epsrevenue estimateactual revenuerelease linkconference calldetailsnaq viewnaq viewlistenqviewlistenqviewnaq million millionviewlistenqviewlistenqviewlistenqviewlistenqviewnaqviewnadata available from  forward estimates earnings estimates for zafgen nasdaqzfgn eps consensus estimate quarternumber of estimateslow estimatehigh estimateaverage estimateq q q q data provided by zacks investment research dividends dividend history for zafgen nasdaqzfgnno dividend announcements for this company have been tracked by marketbeatcom insider trades insider trading and institutional ownership history for zafgen nasdaqzfgninsider ownership percentage institutional ownership percentage insider trades by quarter for zafgen nasdaqzfgntransaction dateinsider nametitlebuysellnumber of sharesaverage share pricetotal transactiondetailsdennis d kiminsiderbuy  dennis d kiminsiderbuy  frances k hellerdirectorbuy  frances k hellerdirectorbuy  thomas e hughesinsiderbuy  patricia l allencfobuy  frances k hellerdirectorbuy  thomas e hughesinsiderbuy  james e flynninsiderbuy  james e flynninsiderbuy  kevin p starrdirectorsell  avi y goldbergdirectorsell  thomas e hughesceosell  dennis d kiminsidersell  avi y goldbergdirectorsell  avi y goldbergdirectorsell  alicia secorinsiderbuy  data available from  forward headlines headline trends for zafgen nasdaqzfgn latest headlines for zafgen nasdaqzfgn source all sources trusted sources marketbeatcom bloomberg marketwatch motley fool nasdaq reuters seeking alpha the street the wall street journal yahoo finance dateheadlinezafgen inc zfgn scheduled to post earnings on wednesdaywwwamericanbankingnewscom  july  at  amzafgen inc nasdaqzfgn receives consensus rating of hold from analystswwwamericanbankingnewscom  july  at  pmzafgen inc nasdaqzfgn short interest updatewwwamericanbankingnewscom  july  at  ambuzzus stocks on the move yandex us retailers teva tesaro  nasdaqwwwnasdaqcom  july  at  pmzacks investment research lowers zafgen inc zfgn to holdwwwamericanbankingnewscom  july  at  pmdennis d kim acquires  shares of zafgen inc nasdaqzfgn stockwwwamericanbankingnewscom  july  at  pmzacks brokerages expect zafgen inc zfgn to post  earnings per sharewwwamericanbankingnewscom  july  at  pmzafgen inc zfgn lifted to sell at valuenginewwwamericanbankingnewscom  july  at  pmzafgen inc nasdaqzfgn rating increased to buy at zacks investment researchwwwamericanbankingnewscom  july  at  amzafgen inc zfgn receives average rating of hold from analystswwwamericanbankingnewscom  june  at  pm analysts anticipate zafgen inc zfgn to announce  earnings per sharewwwamericanbankingnewscom  june  at  pmzafgen to present at the jmp securities life sciences conference  globenewswire press releaseglobenewswirecom  june  at  pmzafgen to present at the jmp securities life sciences conferencefinanceyahoocom  june  at  amzafgen zfgn announces new data highlighting potential of zgn for the treatment of type  diabetes  obesity  streetinsidercomwwwstreetinsidercom  june  at  amzafgen presents new data highlighting potential of zgn for the treatment of type  diabetes and obesity at the american diabetes association’s th annual scientific sessionsfinanceyahoocom  june  at  amzafgen to present two latebreaking abstracts for zgn at the american diabetes association th scientific sessions financeyahoocom  june  at  amzafgen inc zfgn downgraded by valuengine to strong sellwwwamericanbankingnewscom  june  at  pmzafgen inc zfgn given consensus recommendation of hold by brokerageswwwamericanbankingnewscom  may  at  pmzafgen inc zfgn downgraded by zacks investment researchwwwamericanbankingnewscom  may  at  amfy eps estimates for zafgen inc zfgn raised by leerink swannwwwamericanbankingnewscom  may  at  amfy earnings estimate for zafgen inc issued by suntrust banks zfgnwwwamericanbankingnewscom  may  at  aminsider buying zafgen inc zfgn insider purchases  shares of stockwwwamericanbankingnewscom  may  at  pmzafgen reports first quarter  financial results  globenewswire press releaseglobenewswirecom  may  at  pmzafgens second actseekingalphacom  may  at  pmzafgen inc zfgn issues earnings results misses expectations by  epswwwamericanbankingnewscom  may  at  pmzafgen inc zfgn raised to buy at zacks investment researchwwwamericanbankingnewscom  may  at  amzafgen reports first quarter  financial resultsfinanceyahoocom  may  at  pmzafgen reports q lossfinanceyahoocom  may  at  pmzafgen updates on obesity drug  seeking alphaseekingalphacom  may  at  pmzafgen gets one last fat chance  seeking alphaseekingalphacom  may  at  pmzafgen inc zfgn scheduled to post quarterly earnings on mondaywwwamericanbankingnewscom  may  at  amzafgen inc zfgn scheduled to post earnings on mondaywwwamericanbankingnewscom  may  at  amzafgen zfgn reports positive topline phase  data for zgn  streetinsidercomwwwstreetinsidercom  may  at  amzafgen announces positive topline phase  data for zgn a second generation metap inhibitorfinanceyahoocom  may  at  amzafgen rebounds with a safer obesity drug targeting diabeticsfinanceyahoocom  may  at  amedited transcript of zfgn earnings conference call or presentation mar pm gmtfinanceyahoocom  may  at  amedited transcript of zfgn earnings conference call or presentation may pm gmtfinanceyahoocom  may  at  pmzafgen inc zfgn receives average recommendation of hold from brokerageswwwamericanbankingnewscom  may  at  pmzafgen zfgn earns daily coverage optimism rating of wwwamericanbankingnewscom  may  at  amzafgen inc zfgn expected to post earnings of  per sharewwwamericanbankingnewscom  april  at  pmzafgen zfgn getting somewhat critical press coverage alphaone reportswwwamericanbankingnewscom  april  at  amzafgen zfgn receiving somewhat positive press coverage report showswwwamericanbankingnewscom  april  at  pmzafgen zfgn earns daily media impact rating of wwwamericanbankingnewscom  april  at  amzafgen inc zfgn research coverage started at roth capitalwwwamericanbankingnewscom  april  at  amsomewhat negative media coverage somewhat likely to effect zafgen zfgn share pricewwwamericanbankingnewscom  april  at  am analysts expect zafgen inc zfgn will announce earnings of  per sharewwwamericanbankingnewscom  april  at  pmzafgen inc zfgn receives consensus recommendation of hold from analystswwwamericanbankingnewscom  april  at  pmshort interest in zafgen inc zfgn declines by wwwamericanbankingnewscom  april  at  amzafgen inc financialsfinanceyahoocom  march  at  amzafgen reports fourth quarter and full year  financial resultsusrdyahoocom  march  at  am social chart zafgen zfgn chart for friday july   this page was last updated on  by marketbeatcom staff foresite capital management ii llc company profile  bloomberg feedback foresite capital management ii llc private company company profile sector financials industry asset management subindustry wealth management foresite capital management ii llc operates as an investment management company the company invests in healthcare sectors including therapeutics medical devices and diagnostics foresite capital management ii serves customers in the states of california and new york corporate information address  montgomery street suite  san francisco ca  united states phone  fax  web url wwwforesitecapitalcom from the web sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data creative commons — attributionsharealike  unported — cc bysa  skip to content menu help us build a vibrant collaborative global commons donate now creative commons creative commons license deed attributionsharealike  unported cc bysa  this is a humanreadable summary of and not a substitute for the license disclaimer you are free to share — copy and redistribute the material in any medium or format adapt — remix transform and build upon the material for any purpose even commercially the licensor cannot revoke these freedoms as long as you follow the license terms under the following terms attribution — you must give appropriate credit provide a link to the license and indicate if changes were made you may do so in any reasonable manner but not in any way that suggests the licensor endorses you or your use attribute this work sharealike — if you remix transform or build upon the material you must distribute your contributions under the same license as the original no additional restrictions — you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits notices you do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation no warranties are given the license may not give you all of the permissions necessary for your intended use for example other rights such as publicity privacy or moral rights may limit how you use the material learn more about cc licensing or use the license for your own material this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work make a donation this page is available in the following languages castellano castellano españa català dansk deutsch english esperanto français galego hrvatski indonesia italiano latviski lietuvių melayu nederlands norsk polski português português br română slovenščina suomeksi svenska türkçe íslenska česky ελληνικά беларуская русский українська العربية پارسی     한국어 this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work when you share everyone wins contribute today to creative commons     disclaimer this deed highlights only some of the key features and terms of the actual license it is not a license and has no legal value you should carefully review all of the terms and conditions of the actual license before using the licensed material creative commons is not a law firm and does not provide legal services distributing displaying or linking to this deed or the license that it summarizes does not create a lawyerclient or any other relationship what does attribute this work mean the page you came from contained embedded licensing metadata including how the creator wishes to be attributed for reuse you can use the html here to cite the work doing so will also include metadata on your page so that others can find the original work as well the applicable mediation rules will be designated in the copyright notice published with the work or if none then in the request for mediation unless otherwise designated in a copyright notice attached to the work the uncitral arbitration rules apply to any arbitration more info if supplied you must provide the name of the creator and attribution parties a copyright notice a license notice a disclaimer notice and a link to the material cc licenses prior to version  also require you to provide the title of the material if supplied and may have other slight differences more info in  you must indicate if you modified the material and retain an indication of previous modifications in  and earlier license versions the indication of changes is only required if you create a derivative marking guide more info you may also use a license listed as compatible at httpscreativecommonsorgcompatiblelicenses more info a commercial use is one primarily intended for commercial advantage or monetary compensation more info merely changing the format never creates a derivative more info the license prohibits application of effective technological measures defined with reference to article  of the wipo copyright treaty more info the rights of users under exceptions and limitations such as fair use and fair dealing are not affected by the cc licenses more info you may need to get additional permissions before using the material as you intend more info foresite capital  financial services firm san francisco california  brightscope advisor pages getsearchtypedisplaynamesearchtype advisor funds firms k plans back to top homefirmpagesforesite capital foresite capital overviewarticlesholdingsassetsservicesadvisorsleadershipfees share foresite capital overviewarticlesholdingsassetsservicesadvisorsleadershipfees overview description foresite capital is a ria based in sf ca with b in aum information type ria head quarters sf ca  of employees  total assets  website location  montgomery st sf ca   articles insights there are no insights from this firm to display at this time procter  gamble plans competitive but exposure to company stock a risk to participants brightscope editorial firm links there are no links for this firm to display at this time holdings etf holdings there is no etf holding data from this firm to display at this time assets assets last updated on march   b total assets under management na total assets under advisement  accounts m estimated average account balance services firm services there is no services data available to display at this time firm client types advisors current advisors  of advisors  there are no advisors from this firm to display at this time affiliated investment advisors and broker dealers name type total assets foresite capital ia management llc   foresite capital iiia management llc   foresite capital management i llc   foresite capital management ii llc   foresite capital management iii llc   foresite capital va management llc   foresite capital vb management llc   foresite capital vc management llc   foresite capital vd management llc   leadership ownership there is no ownership data available to display at this time executives and control persons name title tenure date  ownership james bruce tananbaum manager trustee july   to  dana shonfeld tananbaum trustee july   to  dennis drew ryan chief financial officer managing director and chief compliance officer january  less than  source sec fees types of compensation arrangements percentage of assets performancebased fees company info about us newsroom careers contact blog explore k plan ratings advisor pages fund pages financial insights faq for advisors advisor pages spyglass for enterprise beacon social facebook twitter linkedin legal privacy policy terms of use copyright   brightscope inc all rights reserved your use of this service is subject to ourterms of useandprivacy policy information is provided as is and solely for informational purposes not for investment purposes or advicebrightscope is not a fiduciary under erisa brightscope is not endorsed by or affiliated with finra brightscope  cio  fww  global custodian  investor economics  liquidmetrix  market metrics  matrix solutions  planadviser  plan for life  plansponsor  simfund  strategic insight  the trade  strategic insight inc all rights reserved no reproduction without prior authorizations brightscope  advisor pages  find a financial advisor or advisory firm getsearchtypedisplaynamesearchtype advisor funds firms k plans general search advisors advisory firms financial qa k plans funds search home    brightscope advisor pages    find a financial advisory firm advisor search firm search advisors by city find a financial advisory firm search firm name active firms only city state alabama alaska american samoa arizona arkansas california colorado connecticut delaware district of columbia florida georgia guam hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota northern marinara islands ohio oklahoma oregon pennsylvania puerto rico rhode island south carolina south dakota tennessee texas utah vermont virgin islands virginia washington west virginia wisconsin wyoming firm service areas financial planning estate planning comprehensive financial planning retirement planning college planning charitable planning other financial planning tax planning insurance life insurance health insurance longterm care insurance annuities property  casualty insurance business insurance other insurance pension consulting k b  defined benefit other pension consulting portfolio management individuals andor small businesses investment companies businesses or institutional clients other portfolio management accounting  tax tax advice other tax legal legal planning legal advice other legal other publication of periodicals or newsletters security ratings or pricing services market timing services selection of other advisors educational seminarsworkshops see all service areas find filters financialplanningfindfirm compensation arrangements no preference fixed fees  hourly charges  performancebased fees  none  fee only  assets under mgmt no preference   k  m  m  m  m  m  m  b  b  avg account balance no preference   k  k  k  k  m  m  m  m  m  financial advisory firm search results  results merrill lynch pierce fenner  smith incorporated ny ny  advisors  aum  b wells fargo advisors llc st louis mo  advisors  aum  b jp morgan securities llc manhattan ny  advisors  aum  b morgan stanley smith barney llc harrison ny  advisors  aum  b lpl financial llc boston ma  advisors  aum  b edward d jones  co lp des peres mo  advisors  aum  b ameriprise financial services inc minneapolis mn  advisors  aum  b ubs financial services inc weehawken nj  advisors  aum  b northwestern mutual investment servicesllc milwaukee wi  advisors charles schwab  co inc south beach ca  advisors mml investors services llc pine point ma  advisors  aum  b goldman sachs  co ny ny  advisors  aum  b strategic advisers inc boston ma  advisors  aum  b citigroup global markets inc new york ny  advisors  aum  b raymond james  associates inc st petersburg fl  advisors  aum  b      company info about us newsroom careers contact blog explore k plan ratings advisor pages fund pages financial insights faq for advisors advisor pages spyglass for enterprise beacon social facebook twitter linkedin legal privacy policy terms of use copyright   brightscope inc all rights reserved your use of this service is subject to ourterms of useandprivacy policy information is provided as is and solely for informational purposes not for investment purposes or advicebrightscope is not a fiduciary under erisa brightscope is not endorsed by or affiliated with finra brightscope  cio  fww  global custodian  investor economics  liquidmetrix  market metrics  matrix solutions  planadviser  plan for life  plansponsor  simfund  strategic insight  the trade  strategic insight inc all rights reserved no reproduction without prior authorizations team  foresite capital strategy portfolio about team news contact our team investment team specifically constructed to identify evaluate and fund what we believe are the best opportunities in healthcare each member of our team brings a diverse and complementary set of skills experience and networks to help accelerate company growth foresite’s principals draw on their track record of developing and launching revolutionary healthcare products and leading financings with successful outcomes alvin tam trading operations manager brett zbar managing director collin yangwong investment analyst dennis d ryan cfo  managing director dorothy margolskee managing director james klinect quantitative analyst jim tananbaum ceo  managing director luke bagaason investment analyst matthew buten managing director michael rome senior analyst molly he venture partner noah dennis investment analyst phil kallos director of engineering rhonda kaufman director richard lau senior investment analyst spencer knight data scientist stephen c peterson senior investment analyst tony wiemelt associate director portfolio  foresite capital strategy portfolio about team news contact portfolio featured companies revolutionizing type  diabetes and obesityintarcias device is a matchsticksized osmotic pump that delivers glp glucagonlike peptide in a manner that avoids the need for regular painful injections while producing efficacy and tolerability resultsprotecting people from food allergensaimmune’s characterized oral desensitization immunotherapy codit™ system combines proprietary product candidates with gradual controlled updosing protocols to obtain meaningful desensitization to food allergens changing the definition of sequencingwith the gemcode platform x genomics researchers can now find structural variants haplotypes and other valuable long range information while leveraging existing sequencing workflowsaddressing glaucoma with tripleaction eyedropsaerie is developing firstinclass oncedaily eye drops with the ability to reduce intraocular pressure iop in patients with openangle glaucoma and ocular hypertensionreversing tumors associated with immunosuppressionarcus is pursuing smallmolecule and proteinbased therapeutics to block active immunosuppression pathways and selectively stimulate the tumorkilling activity of effector immune cellsdeveloping therapeutic antibodies to maximize efficacyalders ald is a novel monoclonal antibody targeting calcitonin generelated peptide cgrp in phase  trials for the prevention of migraine headaches full portfolio  any biopharmaceuticalbiotechnologydrugdevice combinations and medical devicesgenomics tools and data sciencehealthcare services and data sciencepharmaceuticals team  foresite capital strategy portfolio about team news contact our team investment team specifically constructed to identify evaluate and fund what we believe are the best opportunities in healthcare each member of our team brings a diverse and complementary set of skills experience and networks to help accelerate company growth foresite’s principals draw on their track record of developing and launching revolutionary healthcare products and leading financings with successful outcomes alvin tam trading operations manager brett zbar managing director collin yangwong investment analyst dennis d ryan cfo  managing director dorothy margolskee managing director james klinect quantitative analyst jim tananbaum ceo  managing director luke bagaason investment analyst matthew buten managing director michael rome senior analyst molly he venture partner noah dennis investment analyst phil kallos director of engineering rhonda kaufman director richard lau senior investment analyst spencer knight data scientist stephen c peterson senior investment analyst tony wiemelt associate director about us  foresite capital strategy portfolio about team news contact about foresite what we do we provide growth capital to emerging healthcare leaders with disruptive products and services with the goal of transforming patient care foresite capital typically invests small amounts in its initial investment in a portfolio company  million can invest in private and public securities and can invest significant capital over time   million into portfolio company securities foresite capital’s goal is to help portfolio companies grow from proofofconcept to revenue growth and profitability foresite capital provides strategic insight creativity drive and networks of highvalue professionals in addition to capital to its portfolio companies   we built foresite with a deep multidisciplinary and highly experienced team in order to optimize sourcing evaluation and growth acceleration with more than b in assets under management as of june  we apply insight creativity and drive to earn the trust of our portfolio companies how we work our investment team possesses more than  years of collective experience in the healthcare and investment industries we believe this broad and deep experience has produced a bestinclass network of contacts to help our portfolio companies accelerate growth internally our team functions collaboratively with each member of the team participating at all stages of the investment process foresite capital’s due diligence and decisionmaking process is structured to understand and help portfolio companies mitigate key technical regulatory execution and competitive risks jim tananbaum  foresite capital strategy portfolio about team news contact our team alvin tam brett zbar collin yangwong dennis ryan dorothy margolskee james klinect jim tananbaum luke bagaason matthew buten michael rome molly he noah dennis phil kallos rhonda kaufman richard lau spencer knight stephen peterson tony wiemelt jim tananbaum ceo  managing director highlights founded foresite capital in  cofounded geltex which was acquired for  billion by sanofigenzyme cofounded theravance inc total market cap of b which subsequently changed its name to innoviva inc nasdaq inva and with its spinoff theravance biopharma inc nasdaq tbph the companies have a combined market capitalization of  billion earned bs and bsee from yale university in applied math and computer science and ms from mit md and mba from harvard university member of yale’s university council and the advisory committee of the yale school of engineering  applied science    midas list jim is the founder of foresite capital and an industry leader with  years of healthcare entrepreneurial and investing experience jim focuses on strategic operational and financial opportunities to build franchise healthcare businesses he has been the chief architect of foresite capital’s investment organization structure and investment strategy and has played a significant role in numerous foresite capital portfolio companies prior to founding foresite capital jim cofounded two leading biopharmaceutical companies and two healthcare investment practices while finishing harvard university  medical and business schools and earning an ms from the massachusetts institute of technology mit he founded geltex pharmaceuticals nasdaqgenz which brought two drugs to market for less than  million geltex was acquired in  for  billion when its lead drug renagel renzela had an annual revenue run rate in excess of  million today renzela is estimated to produce close to  billion in annual revenue  years after its launch jim also cofounded and was ceo of theravance inc who share gsk’s respiratory franchise through a joint venture innoviva nasdaq inva and completed a spinoff theravance biopharma inc nasdaq tbph  the two companies have a combined market capitalization of approximately  billion jim’s investment experience includes being a founding partner of prospect venture partners ii and iii and earlier in his career  a partner at sierra ventures where he helped establish its healthcare services investment practice jim has led numerous investments including amira pharmaceuticals acquired by nyse bms amerigroup nasdaq amgp healtheon nasdaqwbmd and jazz pharmaceuticals nasdaq jazz  jim founded foresite capital with the vision of marrying elements of all aspects of his career to create a novel investment platformjim graduated with a bs and bsee from yale university an md from harvard medical school an ms from mit and an mba from harvard business school he has served on the advisory boards and visiting committees to the harvardmit hst program and on yale’s president advisory counsel alvin tam brett zbar collin yangwong dennis ryan dorothy margolskee james klinect jim tananbaum luke bagaason matthew buten michael rome molly he noah dennis phil kallos rhonda kaufman richard lau spencer knight stephen peterson tony wiemelt contact us  foresite capital strategy portfolio about team news contact contact us email us your name your email your number your comment sf  montgomery street suite  san francisco ca  tel    ny  avenue of the americas rd floor new york ny  tel    strategy  foresite capital strategy portfolio about team news contact strategy our focus we are a trusted financial partner with a structure that allows us to partner with portfolio company management to develop complete financing solutions in both private and public markets ​​​​​​ we invest in emerging leaders across all areas of healthcare including therapeutics medical devices diagnostics and services our focus is on the development and commercialization of transformative products that address what we believe are the most critical unmet healthcare needs how were different we are a financial partner at all stages – venture and postventure private and public – partnering at the point where we believe we can make the biggest impact we function as a team participating together in primary diligence and sharing collective ownership of our investment and portfolio management decisions our collaborative team culture allows us to bring an array of unique perspectives and evaluate situations efficiently and effectively we provide a depth and breadth of insights and best practices from our experience with hundreds of companies to each of our ventures we have powerful highquality networks and deep experience across areas of healthcare including marketing sales business development research and development regulatory policy and communications the healthcare sector is experiencing unprecedented innovation driven by understanding vast amounts of biologic and genetic information a change we believe is leading to some of the most impactful medical solutions in decades innovation is increasingly focused on improving care and reducing costs our passion is to use our capital and networks to help build transformative healthcare companies and build a portfolio of companies that significantly impact the quality and effectiveness of the us healthcare system jim tananbaum ceo  managing director foresite capital strategy portfolio about team news contact helping build healthcare leaders we provide capital and support to help companies with transformative products and services become healthcare leaders scaling innovation through close collaboration with visionary entrepreneurs and a relentless focus on innovation and building value we aim to dramatically enhance patient care portfolio developing therapeutic antibodies to maximize efficacyprotecting people from food allergensaddressing glaucoma with tripleaction eyedropschanging the definition of sequencingreversing tumors associated with immunosuppressionrevolutionizing type  diabetes and obesity see full portfolio accelerating growth since our inception in  our strategy has been to offer complete capital solutions to help build categorydefining companies across therapeutics devices diagnostics and healthcare services b assets under management  funds closed  diverse team members news apr  prepare for the digital health revolution apr  foresite capital ceo jim tananbaum featured on the forbes midas list for the third year in a row apr  foresite capital announces ceo jim tananbaum named to forbes’ midas list  apr  adaptimmune raises m for pipeline work kalobios chief says biotech is on track for chagas drug filing see all news alder biopharmaceuticals nasdaqaldr news  analysis alder biopharmaceuticals company profile nasdaqaldr company profile analyst ratings earnings history earnings estimates dividend history insider trade headlines social media chart about alder biopharmaceuticals nasdaqaldr alder biopharmaceuticals inc is a clinicalstage biopharmaceutical company that discovers develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms alders lead pivotalstage product candidate eptinezumab is being evaluated for migraine prevention eptinezumab is a monoclonal antibody that inhibits calcitonin generelated peptide cgrp a protein that is active in mediating the initiation of migraine alder is additionally evaluating ald a preclinical product candidate also in development as a migraine prevention therapy ald is a monoclonal antibody that inhibits pituitary adenylate cyclaseactivating polypeptide pacap another protein that is active in mediating the initiation of migraine clazakizumab alders third program is a monoclonal antibody candidate that inhibits interleukin and is licensed to vitaeris inc industry sector and symbol sector medical industry bio therapeutic drugs subindustry na symbol nasdaqaldr cusip na web wwwalderbiocom capitalizationmarket cap  millionoutstanding shares average prices day moving avg  day moving avg  week range    petrailing pe ratio naforeward pe ratio pe growth sales  book valueannual revenue price  sales book value  per shareprice  book  profitabilityebidta return on equity return on assets debtcurrent ratio quick ratio miscaverage volume  million shsbeta short ratio    frequently asked questions for alder biopharmaceuticals nasdaqaldr what is alder biopharmaceuticals stock symbol alder biopharmaceuticals trades on the nasdaq under the ticker symbol aldr how were alder biopharmaceuticals earnings last quarter alder biopharmaceuticals inc nasdaqaldr released its quarterly earnings results on thursday february rd the company reported  eps for the quarter missing the zacks consensus estimate of  by  during the same period in the prior year the business earned  earnings per share view alder biopharmaceuticals earnings history where is alder biopharmaceuticals stock going where will alder biopharmaceuticals stock price be in   equities research analysts have issued year target prices for alder biopharmaceuticals stock their predictions range from  to  on average they anticipate alder biopharmaceuticals share price to reach  in the next year view analyst ratings for alder biopharmaceuticals what are analysts saying about alder biopharmaceuticals stock here are some recent quotes from research analysts about alder biopharmaceuticals stock  according to zacks investment research alder biopharmaceuticals inc is a clinicalstage biopharmaceutical company it discovers develops and seeks to commercialize therapeutic antibodies it is developing monoclonal antibodies comprising ald for the prevention of migraine and clazakizumab in the treatment of rheumatoid arthritis and psoriatic arthritis alder biopharmaceuticals inc is headquartered in bothell washington    needham  company llc analysts commented results from the ongoing pivotal phase  promise trial in patients with frequent episodic migraines fem are expected this month in the context of positive phase  fem results from all competitor cgrp antibody programs amgn lly teva we think promise’s primary endpoint will generally be inline with the competition however we expect differentiation with key secondary endpoints ≥ reduction in migraine days over weeks  and weeks  which we think will be important for commercial success we maintain our view that there is room for multiple players in the migraine prophylaxis market and we believe alder shares remain underappreciated even in a scenario where promise data are positive but undifferentiated alder’s current ev m reflects treatment of just k patients with eptinezumab in  in our model or  of our estimated m prevention therapy candidates   aegis analysts commented we conducted an indepth analysis of four latestage monoclonal antibodies in development for migraine prevention – see table   who are some of alder biopharmaceuticals key competitors some companies that are related to alder biopharmaceuticals include amarin corporation plc amrn insmed insm neuroderm ndrm acorda therapeutics acor omeros corporation omer aduro biotech adro synergy pharmaceuticals sgyp insys therapeutics insy five prime therapeutics fprx retrophin rtrx keryx biopharmaceuticals kerx aclaris therapeutics acrs flexion therapeutics flxn ziopharm oncology ziop revance therapeutics rvnc epizyme epzm ptc therapeutics ptct and achaogen akao who are alder biopharmaceuticals key executives alder biopharmaceuticals management team includes the folowing people stephen m dow independent chairman of the boardrandall c schatzman phd president chief executive officer directorlarry k benedict executive vice president principal accounting officerjames b bucher jd senior vice president general counselrandal a hassler senior vice president  pharmaceutical operationsjohn a latham phd chief scientific officermark james litton phd chief business officer treasurer and secretaryelisabeth a sandoval chief commercial officerjeffrey tl smith md managing director of alder biopharmaceuticals limitedtimothy m whitaker md chief medical officer who owns alder biopharmaceuticals stock alder biopharmaceuticals stock is owned by many different of institutional and retail investors top institutional investors include emerald advisers inc pa  emerald mutual fund advisers trust  ing groep nv  russell investments group ltd  fox run management llc  and daiwa sb investments ltd  company insiders that own alder biopharmaceuticals stock include jeffrey t l smith john a latham mark james litton randall c schatzman and stephen m dow view institutional ownership trends for alder biopharmaceuticals who sold alder biopharmaceuticals stock who is selling alder biopharmaceuticals stock alder biopharmaceuticals stock was sold by a variety of institutional investors in the last quarter including daiwa sb investments ltd company insiders that have sold alder biopharmaceuticals stock in the last year include jeffrey t l smith john a latham mark james litton and randall c schatzman view insider buying and selling for alder biopharmaceuticals who bought alder biopharmaceuticals stock who is buying alder biopharmaceuticals stock alder biopharmaceuticals stock was bought by a variety of institutional investors in the last quarter including emerald advisers inc pa emerald mutual fund advisers trust ing groep nv fox run management llc and russell investments group ltd view insider buying and selling for alder biopharmaceuticals how do i buy alder biopharmaceuticals stock shares of alder biopharmaceuticals can be purchased through any online brokerage account popular online brokerages include vanguard brokerage services td ameritrade etrade scottrade fidelity and charles schwab what is alder biopharmaceuticals stock price today one share of alder biopharmaceuticals stock can currently be purchased for approximately  marketbeat community rating for alder biopharmaceuticals nasdaq aldrcommunity ranking   out of    outperform votes   vote outperformunderperform votes   vote underperformtotal votes  marketbeats community ratings are surveys of what our community members think about alder biopharmaceuticals and other stocks vote outperform if you believe the stock will outperform the sp  over the long term vote underperform if you believe the stock will underperform the sp  over the long term you may vote once every thirty days analyst ratings consensus ratings for alder biopharmaceuticals nasdaqaldr how are consensus ratings calculated marketbeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months since brokers often use different ratings systems each rating is normalized to a standardized rating score of  sell  hold  buy or  strong buy consensus ratings scores are calculated using the mean average of the number of normalized sell hold buy and strong buy ratings each stocks consensus rating is derived from its calculated consensus ratings score   sell   hold   buy   strong buy marketbeats consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve monthsmarketbeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and marketbeat has received a report that coverage was dropped ratings from certain research firms that issue ratings using purely quantitative methods such as zacks vetr and valuengine are not included in consensus calculations marketbeats consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available dataratings breakdown  hold rating  buy ratingsconsensus ratingbuy score consensus price target   upside analysts ratings history for alder biopharmaceuticals nasdaqaldr show only the most recent rating from each brokerage all ratings for this stock datefirmactionratingprice targetimpact on share pricedetailsneedham  company llcset price targetbuylowaegisreiterated ratingbuylowwells fargo  companyreiterated ratingoutperformhighpiper jaffray companiesreiterated ratingoverweighthighcredit suisse groupdowngradeoutperform  neutral  highleerink swannreiterated ratingoutperformmediumjefferies group llcreiterated ratingbuylowbmo capital marketsreiterated ratingoutperformnabrean capitalinitiated coveragebuynaj p morgan chase  coinitiated coverageoverweightnadata available from  forward earnings earnings history for alder biopharmaceuticals nasdaqaldrearnings history by quarter for alder biopharmaceuticals nasdaq aldrdatequarterconsensus estimateactual epsrevenue estimateactual revenuerelease linkconference calldetailsq viewnaq viewnaqviewlistenq million millionviewlistenq millionviewnaqviewlistenq millionviewnaq millionviewnaqviewlistenq million millionviewnaq million millionviewnaq million millionviewnaq million millionviewnadata available from  forward estimates earnings estimates for alder biopharmaceuticals nasdaqaldr eps consensus estimate quarternumber of estimateslow estimatehigh estimateaverage estimateq q q q data provided by zacks investment research dividends dividend history for alder biopharmaceuticals nasdaqaldrno dividend announcements for this company have been tracked by marketbeatcom insider trades insider trading and institutional ownership history for alder biopharmaceuticals nasdaqaldrinsider ownership percentage insider trades by quarter for alder biopharmaceuticals nasdaqaldrtransaction dateinsider nametitlebuysellnumber of sharesaverage share pricetotal transactiondetailsstephen m dowdirectorbuy  jeffrey t l smithvpsell  mark james littoninsidersell  mark james littoninsidersell  jeffrey t l smithvpsell  john a lathaminsidersell  randall c schatzmanceosell  mark james littoninsidersell  jeffrey t l smithvpsell  john a lathaminsidersell  randall c schatzmanceosell  jeffrey t l smithvpsell  randall c schatzmaninsidersell  jeffrey t l smithvpsell  john a lathaminsidersell  john a lathaminsidersell  randall c schatzmaninsidersell  mark james littoninsidersell  jeffrey t l smithvpsell  john a lathaminsidersell  mark james littoninsidersell  john a lathaminsidersell  randall c schatzmanceosell  randall c schatzmanceosell  mark james littoninsidersell  randall c schatzmanceosell  jeffrey t l smithvpsell  john a lathaminsidersell  randall c schatzmanceosell  stephen m dowdirectorsell  jeffrey t l smithvpsell  john a lathaminsidersell  randall c schatzmanceosell  jeffrey t l smithvpsell  john a lathaminsidersell  jeffrey t l smithvpsell  john a lathaminsidersell  stephen m dowdirectorsell  larry benedictvpsell  john a lathaminsidersell  jeffrey t l smithvpsell  john a lathaminsidersell  jeffrey t l smithvpsell  stephen m dowdirectorsell  stephen m dowdirectorsell  clay b siegalldirectorsell  jeffrey t l smithvpsell  john a lathaminsidersell  john a lathaminsidersell  jeffrey t l smithvpsell  john a lathaminsidersell  randall c schatzmanceosell  jeffrey t l smithvpsell  mark james littoninsidersell  randall c schatzmanceosell  jeffrey t l smithvpsell  as novoinsiderbuy  alan bruce montgomerydirectorbuy  west  limited partne venturesmajor shareholderbuy  data available from  forward headlines headline trends for alder biopharmaceuticals nasdaqaldr latest headlines for alder biopharmaceuticals nasdaqaldr source all sources trusted sources marketbeatcom bloomberg marketwatch motley fool nasdaq reuters seeking alpha the street the wall street journal yahoo finance dateheadlinedelta drone  sixmonth report on the liquidity agreement with louis capital marketsfinanceyahoocom  july  at  pmstephen m dow buys  shares of alder biopharmaceuticals inc aldr stockwwwamericanbankingnewscom  july  at  pmalder biopharmaceuticals nets  million to continue migraine drug developmentwwwbizjournalscom  july  at  pmalder biopharmaceuticals announces closing of public offering of common stockfinanceyahoocom  july  at  pmbiotech movers impax shares jump on fda approval for generic version of concerta  thestreetcomwwwthestreetcom  july  at  pmalder biopharmaceuticals inc nasdaqaldr set to announce quarterly earnings on mondaywwwamericanbankingnewscom  july  at  amalder biopharmaceuticals inc nasdaqaldr given average recommendation of buy by analystswwwamericanbankingnewscom  july  at  pmalder biopharma aldr prices m share offering at shwwwstreetinsidercom  july  at  amalder biopharmaceuticals inc aldr fell to a new low after offeringwwwrttnewscom  july  at  amalder biopharmaceuticals inc announces full exercise of underwriters’ option to purchase additional sharesfinanceyahoocom  july  at  amcramer mea culpa this stocks action is why i say smallcap biotechs are only for speculationfinanceyahoocom  july  at  amheres why alder biopharmaceuticals inc stock is bouncing back  motley foolwwwfoolcom  july  at  pmwhy i say smallcap biotechs are only for speculationfinanceyahoocom  july  at  pmalder biopharmaceuticals cramers top takeawaysfinanceyahoocom  july  at  pmpremarket most active for jul    yndx fold snap mt aldr arna tef qat dal tgt qqq teva  nasdaqwwwnasdaqcom  july  at  pmbuzzus stocks on the move yandex us retailers navigator alder biopharma  nasdaqwwwnasdaqcom  july  at  pmtodays research reports on stocks to watch alder biopharmaceuticals inc and verastem incfinanceyahoocom  july  at  pmheres why alder biopharmaceuticals inc stock is bouncing backfinanceyahoocom  july  at  pmwhy alder biopharmaceuticals inc is sinking today  motley foolwwwfoolcom  july  at  amalder biopharmaceuticals inc prices public offering of common stock  globenewswire press releaseglobenewswirecom  july  at  pmalder biopharmaceuticals inc prices public offering of common stockfinanceyahoocom  july  at  pmmidmorning market update markets open higher fastenal earnings top views  benzingawwwbenzingacom  july  at  pmmidafternoon market update nasdaq up over  msc industrial shares plummet  nasdaqwwwnasdaqcom  july  at  pmbuzzus stocks on the moveocular therapeutix nrg energy alder biopharma cara  nasdaqwwwnasdaqcom  july  at  pmwednesday’s biotech movers ibio inc ibio rallies ocular therapeutix inc ocul tumbles alder biopharmaceuticals inc aldr divesfinanceyahoocom  july  at  pmalder biopharmaceuticals inc aldr is down after offering announcementwwwrttnewscom  july  at  amalder biopharmaceuticals inc nasdaqaldr lifted to buy at zacks investment researchwwwamericanbankingnewscom  july  at  pmalder biopharmaceuticals inc announces commencement of public offering of common stock  globenewswire press releaseglobenewswirecom  july  at  pmalder biopharmaceuticals inc announces commencement of public offering of common stockfinanceyahoocom  july  at  pmaegis reiterates buy rating for alder biopharmaceuticals inc nasdaqaldrwwwamericanbankingnewscom  july  at  amfy eps estimates for alder biopharmaceuticals inc cut by leerink swann aldrwwwamericanbankingnewscom  june  at  amalder biopharmaceuticals inc aldr downgraded by valuengine to strong sellwwwamericanbankingnewscom  june  at  pmalder biopharma plummets after results of eptinezumab  phase trial  benzingawwwbenzingacom  june  at  pmalders headache worsens  seeking alphaseekingalphacom  june  at  pmalders shares dip despite positive migraine trial resultswwwzackscom  june  at  pmalder biopharmaceuticals inc selloff a buying opportunity needham weighs infinanceyahoocom  june  at  pmalders shares dip despite positive migraine trial resultsfinanceyahoocom  june  at  pmwells fargo  company reiterates outperform rating for alder biopharmaceuticals inc aldrwwwamericanbankingnewscom  june  at  pmalder biopharmaceuticals inc aldr earns buy rating from needham  company llcwwwamericanbankingnewscom  june  at  pmalder biopharmaceuticals aldr overweight rating reaffirmed at piper jaffray companieswwwamericanbankingnewscom  june  at  pmalder biopharmaceuticals inc aldr rating lowered to neutral at credit suisse groupwwwamericanbankingnewscom  june  at  ammidday market update crude oil up over  xenon pharmaceuticals shares slide  benzingawwwbenzingacom  june  at  pmalder shares plummet almost  despite positive data aralez pops on patent victory biotech movers  thestreetcomwwwthestreetcom  june  at  pmimplied volatility surging for alder biopharmaceuticals aldr stock options  nasdaqwwwnasdaqcom  june  at  pmalder biopharma stock drops nearly  as investors shrug off positive migraine drug results  marketwatchwwwmarketwatchcom  june  at  pmalder’s flagship migraine drug trial posts strong results — and so does the placebofinanceyahoocom  june  at  pmpiper jaffray defends alder despite stock slump looks to whats next in migraine managementwwwbenzingacom  june  at  pmalder biopharmaceuticals announces positive eptinezumab phase  results for prevention of frequent episodic migrainefinanceyahoocom  june  at  pmalders migraine drug meets main goal in latestage studyfinanceyahoocom  june  at  pmimplied volatility surging for alder biopharmaceuticals aldr stock optionsfinanceyahoocom  june  at  pm social chart alder biopharmaceuticals aldr chart for friday july   this page was last updated on  by marketbeatcom staff foresite capital management ii llc top holdings whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active foresite capital management ii llc • san francisco ca how do i update this listing foresite capital management ii is based out of san francisco their last reported f filing for q  included  in managed f securities and a top  holdings concentration of  foresite capital management iis largest holding is aimmune therapeutics inc with shares held of  whalewisdom has at least  f filings in our database for foresite capital management ii summary f holdings ind managers dg insider form  download f summary to excel download f summary to excel create email alert × email notification log in or signup to see more advanced email alert options such as selecting any type of sec form multiple filers or classes of filers and much more or to simply have an email sent to you whenever we receive a new f filing from foresite capital management ii llc enter your email address below and choose submit your email cancel  top buys name change derm dermira inc  epzm epizyme inc  jnce jounce therapeutics  blcm belcum phamcls  orex orexigen therapeuti   top sells name change nstg nanostring technolo  aldr alder biopharm  nvet nexvet biopharma plc  zfgn zafgen inc   f holdings summary stock port aimt aimmune therapeutics inc  aeri aerie pharmaceuticals  epzm epizyme inc  aldr alder biopharm  nstg nanostring technologies  see all holdings  f activity market value  million prior market value  million new purchases stocks additional purchases stocks sold out of stocks reduced holdings in stocks top  holdings  turnover   turnover alt   time held top quarters time held top quarters time held all quarters  turnover is calculated by taking the  of new holdings initial purchases  the  of positions sold out of not just reduced divided by the total  of holdings for the quarter  alt turnover is calculated by taking either the total mv of new purchases or the mv of securities sold whichever is less divided by the total mv of the fund  f sector allocation over time fund metrics you are limited to the prior  quarters of f filings subscribe to whalewisdom to view all filing data for foresite capital management ii llc portfolio performance top  equalweighted holdings last updated on  performance for q   performance last  quarters  performance metrics stats are not available for the latest quarter backtester use whalewisdoms backtester tool to test how a hypothetical portfolio would have performed with different investment strategies research one or more filers performance and then optimize their portfolios to match your own investment goals start with one of our predefined groups or create your own view the backtesting whitepaper and the getting started page for additional help take a tour save changes to tracked backtest saving generate report at least one fund must be selected before running a backtest  ending sector allocation quarter to view current combined fdg q  f filings q  f filings q  f filings q  f filings q  f filings q  f filings q  f filings q  f filings q  f filings subscription required q  f filings subscription required refresh advanced export download csv download excel xlsx download tsv click to see additional filters security types shares calls puts principal changes in holdings new position added to position reduced position closed out position no change ranking is in the top minimum  of shares stock ticker is etf yesno refresh edit columns shares are split adjusted × report an error your name optional your email optional error to report or any other commentsrequired cancel click here to report any possible errors with this listing f filings available   fhr subscription required   fhr subscription required   fhr subscription required   fhr subscription required   fhr subscription required   fhr subscription required   fhr subscription required   fhr subscription required   fhr subscription required   fhr subscription required × csv export module this will schedule a job to export all requested f holdings data for this filer when completed an email will be sent to the email address you specify containing a link to download the zip file of the csv files you requested output type output all f holdings into a single csv file output all f holdings into separate csv files per quarter columns to include filer name stock name stock ticker quarter date type of security current shares held current market value previous shares held previous market value current  of portfolio previous  of portfolio current rank previous rank change in shares type of change sector f quarters to include         email address to send data to cancel schedule export schedule d and g events since  subscription required form   nonderivative insider transactions since  loading elevate your investments try it for free foresite capital  financial services firm san francisco california  brightscope advisor pages getsearchtypedisplaynamesearchtype advisor funds firms k plans back to top homefirmpagesforesite capital foresite capital overviewarticlesholdingsassetsservicesadvisorsleadershipfees share foresite capital overviewarticlesholdingsassetsservicesadvisorsleadershipfees overview description foresite capital is a ria based in sf ca with b in aum information type ria head quarters sf ca  of employees  total assets  website location  montgomery st sf ca   articles insights there are no insights from this firm to display at this time procter  gamble plans competitive but exposure to company stock a risk to participants brightscope editorial firm links there are no links for this firm to display at this time holdings etf holdings there is no etf holding data from this firm to display at this time assets assets last updated on march   b total assets under management na total assets under advisement  accounts m estimated average account balance services firm services there is no services data available to display at this time firm client types advisors current advisors  of advisors  there are no advisors from this firm to display at this time affiliated investment advisors and broker dealers name type total assets foresite capital ia management llc   foresite capital iiia management llc   foresite capital management i llc   foresite capital management ii llc   foresite capital management iii llc   foresite capital va management llc   foresite capital vb management llc   foresite capital vc management llc   foresite capital vd management llc   leadership ownership there is no ownership data available to display at this time executives and control persons name title tenure date  ownership james bruce tananbaum manager trustee july   to  dana shonfeld tananbaum trustee july   to  dennis drew ryan chief financial officer managing director and chief compliance officer january  less than  source sec fees types of compensation arrangements percentage of assets performancebased fees company info about us newsroom careers contact blog explore k plan ratings advisor pages fund pages financial insights faq for advisors advisor pages spyglass for enterprise beacon social facebook twitter linkedin legal privacy policy terms of use copyright   brightscope inc all rights reserved your use of this service is subject to ourterms of useandprivacy policy information is provided as is and solely for informational purposes not for investment purposes or advicebrightscope is not a fiduciary under erisa brightscope is not endorsed by or affiliated with finra brightscope  cio  fww  global custodian  investor economics  liquidmetrix  market metrics  matrix solutions  planadviser  plan for life  plansponsor  simfund  strategic insight  the trade  strategic insight inc all rights reserved no reproduction without prior authorizations